Trial · NCT01234454
Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
NCT01234454, Not applicable, Completed, University of North Carolina, Chapel Hill
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI. Trials, record NCT01234454. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01234454
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
- NCT number
- NCT01234454
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 34 participants, actual
- Lead sponsor
- University of North Carolina, Chapel Hill
- Conditions
- Schizophrenia
- Interventions
- Risperidone, Olanzapine
- First posted
- 2010-11-04
- Last updated
- 2015-04-03
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neurocognitive Assessment Procedure | Baseline, after four weeks of Thiothixine, then follow-up after 8 weeks | Composite score derived from the neurocognitive battery used in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia clinical trial and the Brief Assessment of Cognition in Schizophrenia (BACS). |
| Primary | fMRI activation Tasks | Baseline, after four weeks of Thiothixine, then follow-up after 8 weeks | During MR imaging subjects performed one visual-auditory target detection task and one auditory oddball task. Subjects completed runs consisting of 160 trials with a total duration of approximately 4 min. During odd numbered runs, subjects performed a visual target detection task. During even numbered runs, subjects performed an auditory target detection task. |
| Secondary | Performance accuracy on Visual-auditory target detection task | Baseline, after four weeks of Thiothixine, then follow-up after 8 weeks | Per fMRI activation tasks. For the visual task, subjects were asked to pay attention to a screen where two types of stimuli were displayed: 1) Standards were squares of varying size and color that comprised \~95% of trials 2) Targets were circles of varying zize and colors that were presented irriegularly on \~5% of trials. The onsets of successive Targets were separated by a minimum of 15 seconds. |
| Secondary | Performance accuracy on Auditory oddball target detection task | baseline, after four weeks of Thiothixine, then follow-up after 8 weeks | Per fMRI activation tasks. Subjects were asked to pay attention to attend to auditory stimuli presented at a rate of one per 500 msecs for each run. Standards were 500 msec duration 440 Hz pure tones that were presented on \~95% of trials. Frequency-deviant Target tones were 500msec duration 800 Hz pure tones presented irregularly on \~5% of trials. The onsets of successive deviant tones were separated by a minimum of 15 seconds. During both tasks subjects were instructed to press a button whenever a Target was presented. No overt or covert response was required of Standards. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Oddball Target Detection | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01234454
GET https://conductscience.org/api/trials/v1/NCT01234454/registered